| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 156, Issue 9 3357-3365, Copyright © 1996 by American Association of Immunologists
ARTICLES |
JB Rao, RS Chamberlain, V Bronte, MW Carroll, KR Irvine, B Moss, SA Rosenberg and NP Restifo
Howard Hughes Medical Institute-National Institutes of Health Research Scholars Program, Surgery Branch, National Cancer Institute, Bethesda, MD 20892, USA.
A number of cytokines and costimulatory molecules involved in immune activation have recently been identified including IL-12, a heterodimeric cytokine that supports the development of cell-mediated immunity, and B7-1, a costimulatory molecule involved in the activation of T lymphocytes. We explored the use of these immunomodulants as molecularly defined adjuvants in the function of recombinant anticancer vaccines using a murine model adenocarcinoma, CT26, transduced with a model Ag, beta-galactosidase (beta-gal). Although IL-12 given alone to mice bearing tumors established for 3 days did not have consistent antitumor activity, a profound therapeutic effect was observed when IL- 12 administration was combined with a recombinant vaccinia virus (rVV) encoding beta-gal called VJS6. On the basis of the reported synergistic effects of IL-12 and the costimulatory molecule B7-1 (CD80) in vitro, we immunized mice with a double recombinant vaccinia encoding both the model tumor Ag and the costimulatory molecule B7-1, designated B7-1 beta-gal rVV. The adjuvant administration of IL-12 after immunization with this virus significantly enhanced survival in tumor-bearing animals. T cell subset depletions demonstrated that the in vivo activity of IL-12 was largely independent of CD4+ T lymphocytes, whereas the in vivo activity of a B7-1 rVV required both CD4+ and CD8+ T cells to elicit maximal therapeutic effect. To our knowledge, this is the first description of B7-1 and IL-12 cooperation in vivo and represents a novel strategy to enhance the efficacy of recombinant anticancer vaccines.
This article has been cited by other articles:
|
|
 |
|
  C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al. Toll-like Receptors in Tumor Immunotherapy Clin. Cancer Res., September 15, 2007; 13(18): 5280 - 5289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Peterson, H. Harlin, and T. F. Gajewski Immunization With Melan-A Peptide-Pulsed Peripheral Blood Mononuclear Cells Plus Recombinant Human Interleukin-12 Induces Clinical Activity and T-Cell Responses in Advanced Melanoma J. Clin. Oncol., June 15, 2003; 21(12): 2342 - 2348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Nakamori, M. Iwahashi, M. Nakamura, K. Ueda, X. Zhang, and H. Yamaue Intensification of Antitumor Effect by T Helper 1-dominant Adoptive Immunogene Therapy for Advanced Orthotopic Colon Cancer Clin. Cancer Res., June 1, 2003; 9(6): 2357 - 2365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nagarajan and P. Selvaraj Glycolipid-anchored IL-12 Expressed on Tumor Cell Surface Induces Antitumor Immune Response Cancer Res., May 1, 2002; 62(10): 2869 - 2874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Ahlers, I. M. Belyakov, S. Matsui, and J. A. Berzofsky Mechanisms of cytokine synergy essential for vaccine protection against viral challenge Int. Immunol., July 1, 2001; 13(7): 897 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-W. Chen, C.-H. Pan, H.-W. Huan, M.-Y. Liau, J.-R. Chiang, and M.-H. Tao Suppression of Immune Response and Protective Immunity to a Japanese Encephalitis Virus DNA Vaccine by Coadministration of an IL-12-Expressing Plasmid J. Immunol., June 15, 2001; 166(12): 7419 - 7426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Grosenbach, J. C. Barrientos, J. Schlom, and J. W. Hodge Synergy of Vaccine Strategies to Amplify Antigen-specific Immune Responses and Antitumor Effects Cancer Res., June 1, 2001; 61(11): 4497 - 4505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Rempel, M. Wang, and K. T. HayGlass Failure of rIL-12 administration to inhibit established IgE responses in vivo is associated with enhanced IL-4 synthesis by non-B/non-T cells Int. Immunol., July 1, 2000; 12(7): 1025 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Karanikas, J. Lodding, V. C. Maino, and I. F. C. McKenzie Flow Cytometric Measurement of Intracellular Cytokines Detects Immune Responses in MUC1 Immunotherapy Clin. Cancer Res., March 1, 2000; 6(3): 829 - 837. [Abstract] [Full Text]
|
|
|
|
|
|
F. Fallarino and T. F. Gajewski Cutting Edge: Differentiation of Antitumor CTL In Vivo Requires Host Expression of Stat1 J. Immunol., October 15, 1999; 163(8): 4109 - 4113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Drexler, E. Antunes, M. Schmitz, T. Wolfel, C. Huber, V. Erfle, P. Rieber, M. Theobald, and G. Sutter Modified Vaccinia Virus Ankara for Delivery of Human Tyrosinase as Melanoma-associated Antigen: Induction of Tyrosinase- and Melanoma-specific Human Leukocyte Antigen A*0201-restricted Cytotoxic T Cells in Vitro and in Vivo Cancer Res., October 1, 1999; 59(19): 4955 - 4963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Caminschi, E. Venetsanakos, C. C. Leong, M. J. Garlepp, B. W. S. Robinson, and B. Scott Cytokine Gene Therapy of Mesothelioma . Immune and Antitumor Effects of Transfected Interleukin-12 Am. J. Respir. Cell Mol. Biol., September 1, 1999; 21(3): 347 - 356. [Abstract] [Full Text]
|
|
|
|
 |
|
 L. R. Schopf, J. L. Bliss, L. M. Lavigne, C. L. Chung, S. F. Wolf, and J. P. Sypek Interleukin-12 Is Capable of Generating an Antigen-Specific Th1-Type Response in the Presence of an Ongoing Infection-Driven Th2-Type Response Infect. Immun., May 1, 1999; 67(5): 2166 - 2171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Hirschowitz and R. G. Crystal Adenovirus-Mediated Expression of Interleukin-12 Induces Natural Killer Cell Activity and Complements Adenovirus-Directed gp75 Treatment of Melanoma Lung Metastases Am. J. Respir. Cell Mol. Biol., May 1, 1999; 20(5): 935 - 941. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. Schuler, Z. Qin, S. Ibe, N. Noben-Trauth, and T. Blankenstein T Helper Cell Type 1-associated and Cytotoxic T Lymphocyte-mediated Tumor Immunity Is Impaired in Interleukin 4-deficient Mice J. Exp. Med., March 1, 1999; 189(5): 803 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Fernandez, J.-P. Levraud, H. Haddada, M. Perricaudet, and P. Kourilsky High Frequency of Specific CD8+ T Cells in the Tumor and Blood Is Associated with Efficient Local IL-12 Gene Therapy of Cancer J. Immunol., January 1, 1999; 162(1): 609 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Caminschi, E. Venetsanakos, C. C. Leong, M. J. Garlepp, B. Scott, and B. W. S. Robinson Interleukin-12 Induces an Effective Antitumor Response in Malignant Mesothelioma Am. J. Respir. Cell Mol. Biol., November 1, 1998; 19(5): 738 - 746. [Abstract] [Full Text]
|
|
|
|
|
|
M. Toda, R. L. Martuza, H. Kojima, and S. D. Rabkin In Situ Cancer Vaccination: An IL-12 Defective Vector/Replication-Competent Herpes Simplex Virus Combination Induces Local and Systemic Antitumor Activity J. Immunol., May 1, 1998; 160(9): 4457 - 4464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. B. Geldhof, M. Moser, L. Lespagnard, K. Thielemans, and P. De Baetselier Interleukin-12-Activated Natural Killer Cells Recognize B7 Costimulatory Molecules on Tumor Cells and Autologous Dendritic Cells Blood, January 1, 1998; 91(1): 196 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Dorfman, J. L. Schultze, A. Shahsafaei, S. Michalak, J. G. Gribben, G. J. Freeman, G. S. Pinkus, and L. M. Nadler In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation Blood, December 1, 1997; 90(11): 4297 - 4306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Osanto Vaccine Trials for the Clinician: Prospects for Tumor Antigens Oncologist, October 1, 1997; 2(5): 284 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Goedegebuure and T. J. Eberlein Vaccine Trials for the Clinician: Prospects for Viral and Non-Viral Vectors Oncologist, October 1, 1997; 2(5): 300 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Bronte, M. W. Carroll, T. J. Goletz, M. Wang, W. W. Overwijk, F. Marincola, S. A. Rosenberg, B. Moss, and N. P. Restifo Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine PNAS, April 1, 1997; 94(7): 3183 - 3188. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
